Eli Lilly's weight loss drug slashes the risk of diabetes in long-term trial
Eli Lilly’s new GLP‑1/GIP weight‑loss drug, similar to Ozempic, is being hailed by many users and clinicians as a near “wonder drug” for obesity and type 2 diabetes prevention, dramatically reducing appetite and diabetes risk in long‑term trials. Commenters weigh its benefits against concerns over long‑term side effects, muscle and bone loss, the likelihood that weight returns after stopping, and the need for concurrent lifestyle changes like strength training. High cost, uneven insurance coverage, and broader questions about whether such drugs treat symptoms of an unhealthy food environment or represent a necessary medical fix for a systemic obesity crisis are central points of debate.
Efficacy and “wonder drug” framing
- Many commenters describe GLP‑1 drugs (Ozempic/semaglutide, Mounjaro/Zepbound/tirzepatide) as the closest thing to a 21st‑century “wonder drug” for obesity and diabetes.
- Users report dramatic weight loss and much better blood‑sugar control where diet, exercise, and older drugs failed.
- Some see them as non‑surgical alternatives to bariatric procedures.
Mechanism: appetite, brain, and behavior
- Drugs are GLP‑1 (and in tirzepatide’s case, GLP‑1 + GIP) receptor agonists; they reduce appetite, slow gastric emptying, and blunt blood‑sugar spikes.
- Debate: are they “chemically induced intermittent fasting,” generic calorie restriction, or qualitatively different? Consensus: they enforce a calorie deficit mainly by reducing hunger and cravings.
- Some emphasize that hormones/biochemistry, not just “discipline,” underpin eating behavior.
Side effects and long‑term risks
- Commonly reported: GI issues (nausea), possible muscle and lean‑mass loss, potential bone‑density reduction, and retinal concerns in diabetics with rapidly improved glucose.
- One view: decades of GLP‑1 study suggest low overall risk; others insist “you don’t get something for nothing” and worry about yet‑unknown chronic effects.
Durability, regain, and treatment length
- Stopping often leads to return of appetite and weight regain, similar to other weight‑loss methods.
- Some see lifetime use as likely; others hope for “reset” of habits plus exercise (especially strength training) to maintain results.
Cost, patents, and systemic healthcare effects
- Current U.S. prices (~$10–12k/year) are seen as prohibitive; cheaper in some other countries and via compounding pharmacies.
- Discussion of patent timelines and expectation that generics will transform access.
- Unclear net impact on healthcare costs: fewer obesity/diabetes complications vs more people living long enough to incur other expensive conditions.
- Skepticism that U.S. insurance premiums will fall even if population health improves.
Obesity, responsibility, and food environment
- Strong disagreement over “just eat less and move more” vs acknowledging structural and psychological barriers (hyperpalatable food environment, stress, poverty).
- Several argue drugs are necessary to counteract an obesogenic system; others push for systemic fixes to food supply and policy akin to tobacco control.
Eligibility and anecdotes
- Non‑diabetics with obesity are using these drugs; many report unprecedented control over urges, while some still crave “bad” foods.
- Mixed views on using them for modest weight loss vs reserving for obesity and diabetes.